Home > Resources > Whitepapers > Beyond borders 2016: Biotech financing

Beyond borders 2016: Biotech financing

October 20, 2016

The poet and author Robert Louis Stevenson famously advised: “Don’t judge each day by the harvest you reap, but by the seeds you plant.” These are wise words, especially so in today’s uncertain financial climate. Whether large or small, public or private, biotech companies across the industry have taken advantage of the capital that has flowed freely these past two years. They have filled (or refilled) their coffers with cash to drive future R&D and business development agendas.

Spotlight

MedTech Association

MedTech connects New York State’s Bio/Med industry through collaboration, education and advocacy. We are an active association of pharmaceutical, biotech and medical technology companies, their suppliers and service providers, and research institutions.

OTHER WHITEPAPERS

Best Practices for RIM Business Process Automation

whitePaper | December 15, 2022

Regulatory teams at life science companies are finding that effective regulatory information management (RIM) has become critical to their operations.

T Cell Expansion in Small Scale Bioreactors

whitePaper | October 28, 2022

Adoptive cell therapy (ACT), a branch of immunotherapy, offers a promising treatment for chronic viral infections and malignant diseases such as cancer [1]. This innovative approach involves the autologous or allogenic transplant of immune cells into the patient’s body.

Accurate and reliable cell counting using holographic microscopy and machine learning algorithms

whitePaper | August 11, 2022

Reliable and accurate cell counts are crucial for many different purposes such as the maintenance of cell cultures in biological research or in-process controls in industrial bioprocessing.

Recruitment, Retention & Diversity: The Evolution of Patient Engagement in Clinical Trials

whitePaper | January 23, 2023

Recruitment, retention, and diversity are critical elements of clinical trials that, if insufficient, can jeopardize successful trial completion.

A Cornerstone in the Supply Chain of Cell-based Therapies

whitePaper | February 15, 2023

The diverse therapeutic attributes of mesenchymal stromal cells (MSCs) lend to their rapid development as cellular therapeutics. These unique attributes include potent immu nomodulatory properties [1,2], the potential to differentiate into multiple cell lineages.

Advanced Treatments Gene and Cell Therapy

whitePaper | April 26, 2022

Public Policy Projects (PPP) is a global policy institute offering practical analysis and development across a range of sectors, including health and social care.